Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psych Congress Network
The advent of zuranolone may be going beyond postpartum depression, with 87.5% of patients noticing improvements within the first week of treatment for MDD.
Psychiatry November 14th 2023
Psychiatry Advisor
Recent findings indicate a significant association between SSRI use in children and delayed puberty, with an odds ratio of 1.44. This underscores the importance of considering potential developmental impacts when prescribing these medications.
Pediatrics November 7th 2023
A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.
Psychiatry November 7th 2023
MDLinx
Despite the potential benefits of ketamine in treating a range of neurological and psychiatric disorders, the FDA has issued warnings about the potential risks associated with its use, emphasizing the need for careful prescription and clinical oversight.
Neurology November 7th 2023
Psychiatrist.com
The study suggests that approximately one heated yoga session per week was associated with significantly greater reduction in depression symptoms than a waitlist control. This finding indicates that heated yoga could be a viable non-medication-based treatment option for patients with moderate-to-severe depression.
Psychiatry November 1st 2023
Johns Hopkins Medicine
In a recent study, researchers have discovered that gamma delta T cells in our intestines can influence our gut microbiome. This influence may extend to our brain functions and potentially impact stress-induced disorders such as depression.
Gastroenterology November 1st 2023